secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0000882095-24-000010
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q1 GAAP loss per share $(3.34) on $3.9B CymaBay charge; guidance slashed
-------------------------------------------------------------------------------

- GAAP diluted EPS loss $(3.34) vs $0.80 YoY; non-GAAP loss $(1.32) vs $1.37.
- Revenue up 5% to $6.7B; base business ex-Veklury up 6% to $6.1B.
- Biktarvy up 10% to $2.9B; Oncology up 18% to $789M.
- Full-year GAAP EPS guidance cut to $0.10–$0.50 from $5.15–$5.55; non-GAAP to $3.45–$3.85 from $6.85–$7.25.
- Cash $4.7B; operating cash flow $2.2B; dividends paid $990M; $400M stock buyback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209524000010/0000882095-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209524000010/gild-20240425.htm
  HTML page:      https://secwatch.observer/filing/0000882095-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer